Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DREAMM 7
2018-003993-29Phase 3Unknown
- Sponsor
- GSK
- Start
- Feb 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of belantamab mafodotin, daratumumab, bortezomib and dexamethasone in multiple myeloma (MM) (2 arms), sponsored by GSK. Primary endpoint: Progression-free survival. Status: unknown.
02
Drugs
belantamab mafodotindaratumumabbortezomibdexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2018-003993-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003993-29.